Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.66 |
| ▸ | DAO | P14920 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NQO1 | P15559 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1585486 | 0.79 | IDH1 (1.00) | IDH1DAOKDM4E | |
| SCHEMBL584803 | 0.78 | IDH1 (0.54) | IDH1DAOKDM4EALDH1A1HPGD | |
| SCHEMBL11483794 | 0.77 | IDH1 (0.57) | IDH1DAOKDM4EALDH1A1HPGD | |
| Carbonarone A SCHEMBL21638076 | 0.74 | IDH1 (0.63) | IDH1DAOKDM4EALDH1A1HPGD | |
| SCHEMBL12090870 | 0.74 | TYR (0.41) | DAOKDM4EALDH1A1POLBNQO1 | |
| SCHEMBL27719076 | 0.74 | IDH1 (0.58) | IDH1DAOALDH1A1HPGDLMNA | |
| SCHEMBL2468840 | 0.73 | IDH1 (0.54) | IDH1DAOKDM4EALDH1A1POLB | |
| SCHEMBL12723378 | 0.73 | IDH1 (0.54) | IDH1DAOPOLB | |
| SCHEMBL15978541 | 0.73 | IDH1 (0.53) | IDH1DAOKDM4EALDH1A1HPGD | |
| SCHEMBL4141025 | 0.72 | TYR (0.64) | IDH1DAOKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065857-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | BAYLOR COLLEGE OF MEDICINE (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065857-A1 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY | DDX18, FPR1, DCXR | IDH1 1207/4885DAO 438/4885KDM4E 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.